UNSPSC 51181576: Zenarestat

This classification denotes an aldose reductase inhibitor with the molecular formula C17H11BrClFN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 180C9PJ8JT, chemically known as 3-(4-bromo-2-fluorobenzyl)-7-chloro-3,4-dihydro-2,4-dioxo-1(2h)-quinazolineacetic acid but generally known as zenarestat, which bears US NIH Compound Identifier 5724. European Medicines Agency schedules Zenarestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00145MIG.

UNSPSC 51181576 Zenarestat (Commodity) covers generic pharmaceutical products distributed through state and local cooperative purchasing arrangements, as evidenced by recent solicitations seeking manufacturers to supply multiple drug formulations with specified National Drug Codes to authorized wholesalers serving government facilities. The work involves providing comprehensive pricing data, product compliance documentation, and supply chain partnerships rather than direct end-user delivery. State and local procurement under this code flows through cooperative purchasing alliances that aggregate demand across multiple participating jurisdictions and states, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving as a representative issuing body that coordinates procurement on behalf of member agencies including state departments and subordinate facilities across Oregon and other participating states.

The MMCAP solicitation issued January 20, 2026 (RFP S1070000015802, due March 26, 2026) exemplifies current activity: manufacturers must supply generic multi-source pharmaceuticals with specific NDC codes, maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), hold current Good Manufacturing Practices certification and Drug Supply Chain Security Act compliance, and accept a 3 percent administrative fee on all contract purchases. Evaluation emphasizes price competitiveness (75 percent weight), with secondary criteria covering pricing format options (flat price, net price, or WAC-minus structures), EDI capability, and administrative compliance. Contract terms span two years for new vendors with optional MMCAP extensions, effective July 1, 2026. The procurement does not identify specific set-aside restrictions or disadvantaged-enterprise preferences in available documentation.